Sarah L. Hilderbrand

NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme

David M. Peereboom, Manmeet S. Ahluwalia, Xiaobu Ye et al. · Neuro-Oncology · 2013 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17

First‐line treatment of essential hypertension: A real‐world analysis across four antihypertensive treatment classes

Manfred Stapff, Sarah L. Hilderbrand · Journal of Clinical Hypertension · 2019 · 39 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Phase 1 study of N 1,N 11-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma

Lipika Goyal, Jeffrey G. Supko, Jordan Berlin et al. · Cancer Chemotherapy and Pharmacology · 2013 · 24 citations

Medicine, Oncology, Pharmacology +13

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Lewis B. Silverman, Traci M. Blonquist, Sarah K. Hunt et al. · Blood · 2016 · 16 citations

Medicine, Oncology, Pediatrics +15